Oral semaglutide: the three approved pills and how they differ

For years the only semaglutide pill was Rybelsus, a diabetes drug. Now there are three approved tablets, with distinct names, strength sets and labeled uses, plus a separate GLP-1 pill from Eli Lilly. The names overlap enough to confuse anyone. This guide sorts them out, starting with the one most people searching for “oral semaglutide” want: the Wegovy pill for weight.

Approved semaglutide tablets: different formulations and indications

The Wegovy pill treats weight and lowers heart-event risk. Rybelsus and its newer version, renamed Ozempic tablets, treat type 2 diabetes. All three contain semaglutide, but the label is blunt that the diabetes tablets “are not substitutable on a mg-to-mg basis” ^[2]. Wegovy tablets have adult weight and cardiovascular indications; the diabetes tablets have their own adult indications. The tablet does not inherit every indication of the corresponding injection.

What happened to Rybelsus? Novo Nordisk developed a second formulation, called R2. FDA approved renaming it “Ozempic tablets” on January 30, 2026 ^[7]. The original Rybelsus tablets are being phased out; FDA’s drug shortage database listed them as “To Be Discontinued” in June 2026 ^[8]. Rybelsus also gained a heart-risk indication in October 2025, based on the SOUL trial ^[6].

How the pill gets absorbed, and why the morning rule matters

Follow the labeled fasting and water instructions because administration conditions affect semaglutide exposure. The Wegovy label says to take the tablet “once-daily on an empty stomach in the morning with water (up to 4 ounces),” and to “wait at least 30 minutes before eating food, drinking beverages or taking other oral medications” ^[1]. Rybelsus and Ozempic tablets carry the same rule ^[2].

The reason is chemistry. Semaglutide is a peptide, and the stomach normally breaks peptides down. The tablets are “co-formulated with SNAC which facilitates the absorption of semaglutide,” and absorption happens mostly in the stomach ^[1]. Estimated absolute bioavailability is formulation-specific: about 1% to 2% for Wegovy and Ozempic tablets, versus 0.4% to 1% for the original Rybelsus formulation ^[2]. Tablet milligrams therefore cannot be converted directly to injection milligrams. Even the two diabetes-tablet formulations have different strengths and labeled switching instructions.

What the Wegovy pill did in trials: 13.6% weight loss at 64 weeks

The approved 25 mg Wegovy pill was tested in OASIS 4. In 307 adults without diabetes, average weight fell 13.6% over 64 weeks, against 2.2% on placebo ^[13]. People on the pill were also more likely to reach 5%, 10%, 15% and 20% weight-loss milestones.

An earlier trial, OASIS 1, used a 50 mg daily tablet and reached 15.1% weight loss at 68 weeks, against 2.4% on placebo ^[14]. That 50 mg dose is not the one FDA approved, so don’t read OASIS 1 as the Wegovy pill’s result.

OASIS 4 and STEP 1 did not compare the approved pill and injection directly. In these separate trials, the 25 mg pill reached 13.6% at 64 weeks and the 2.4 mg injection reached 14.9% at 68 weeks ^[19]. Those are close, but different people, lengths and sites mean you can’t subtract one from the other. These semaglutide trials were funded by Novo Nordisk. OASIS 4’s publication reports a placebo change of −2.2%; the current label’s specified analysis reports −2.4% ^[1]. Keep estimates with their source and analysis rather than combining them into a new comparison.

Heart and diabetes evidence for the tablets

SOUL enrolled 9,650 adults aged 50 or older with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both. Over a median 49.5 months, first major cardiovascular events occurred in 12.0% on oral semaglutide and 13.8% on placebo ^[15]. The hazard ratio of 0.86 (95% CI 0.77–0.96) means a 14% relative reduction in the event hazard, not a 14 percentage-point absolute reduction. PIONEER 6 met its prespecified noninferiority criterion, but its interval crossed 1: HR 0.79, 95% CI 0.57–1.11 ^[16]. That trial alone did not establish cardiovascular superiority or eliminate possible harm.

The Wegovy pill’s heart indication is different. It covers adults with established heart disease and obesity or overweight ^[1], the population studied for the Wegovy injection in SELECT. The label presents SELECT injection outcomes as cardiovascular evidence and pharmacokinetic comparisons for the tablets. OASIS 4 was a weight trial, not a cardiovascular outcome trial. Wegovy tablets are not approved for the injection’s pediatric weight or MASH indications.

Label doses, as the labels state them

These labels distinguish initiation, escalation and maintenance doses. Wegovy tablets use 25 mg daily for maintenance; the lower strengths serve escalation ^[1]. Rybelsus and Ozempic tablets have different strength sets, and their starting doses are not effective for glycemic control ^[2]. Foundayo has a separate formulation and schedule ^[3]. The table is a product reference, not a personal escalation plan; tolerability, interactions and the treatment indication require clinical assessment.

The labels include tables for switching between these products. Switching is your prescriber’s call, not a conversion you should do at home. The mg numbers don’t line up across products, which is the whole point of the “not substitutable” warning.

Side effects: mostly stomach, plus a boxed warning

Stomach side effects are the main story. In OASIS 4, 74.0% of people on the 25 mg pill reported a gastrointestinal adverse event, against 42.2% on placebo ^[13]. The combined Wegovy label lists nausea, diarrhea, vomiting, constipation and stomach pain among the most common reactions ^[1].

The Wegovy label, which covers both the injection and the tablets, carries a boxed warning: semaglutide caused thyroid C-cell tumors in rodents, and “it is unknown whether WEGOVY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans” ^[1]. A personal or family history of medullary thyroid carcinoma or MEN 2 is a contraindication. Serious allergy to the medicine or its ingredients also matters; review the exact product’s contraindications with the prescriber. Rybelsus, Ozempic tablets and Foundayo also list the MTC/MEN 2 contraindication ^{[2] [3]}. Severe or persistent abdominal symptoms, repeated vomiting or dehydration warrant prompt clinical assessment. Tell the anesthesia team about the medication before a procedure: labels describe aspiration reports and uncertainty about how best to reduce that risk.

Pill or injection? The trade-offs that decide it

• Schedule. The pill is daily; the injection is weekly.
• Routine. The semaglutide pill needs an empty stomach and a 30-minute wait every morning. Foundayo can be taken “with or without food” ^[3].
• Needles. The pill has none. For some people that settles it.
• Trial results. 13.6% (pill, 64 weeks) and 14.9% (injection, 68 weeks) in separate trials ^{[13] [19]}.
• Cost. Compare the maintenance strength, offer conditions and supply unit. A starter-tablet price does not establish the continuing medication or clinical-care budget ^[11].
• Long run. Ask about follow-up, tolerability, ongoing access and the plan if treatment changes. A trial average cannot predict an individual’s result or how long treatment will remain appropriate.

The pill-versus-shot question gets its own comparison in Wegovy pill vs Wegovy injection.

What it costs: $149 to $299 a month self-pay, before a program fee

NovoCare sells the Wegovy pill for cash at $149 a month for 1.5 mg, $199 for 4 mg and $299 for 9 mg or 25 mg, with one month defined as a 30-tablet bottle as of this update ^[11]. NovoCare says pricing will be updated after December 31, 2026. Foundayo through LillyDirect starts at $149 a month for 0.8 mg ^[12]. The 2.5 mg dose is also $149 and 5.5 mg is $199, prices Lilly calls temporarily reduced through December 31, 2026. Doses from 9 mg to 17.2 mg are advertised at $299. The 14.5 mg and 17.2 mg prices require refilling within 45 days under the Journey Program; regular prices apply otherwise. Lilly defines a month as 30 days. A prescription and offer eligibility are required, taxes and fees may apply, and Lilly may change or end the offer. Self-pay prices for Rybelsus and Ozempic tablets aren’t quoted here.

A medication offer is only one part of the budget. Ask whether visits, required laboratory work, shipping and membership are included, then separate the initial charge from recurring payments. Compare a written quote with the monthly cost calculator and the program billing checklist. A 30-day supply and a calendar-month charge are different units.

The GLP-1 pill programs comparison and individual reviews help identify questions for a clinic; they do not guarantee a medication, insurance approval or a manufacturer offer. For the distinct pharmacy-prepared route, read compounded semaglutide costs and access and pharmacy checks.

The other GLP-1 pill: Foundayo (orforglipron)

Foundayo is Eli Lilly’s once-daily GLP-1 pill, approved on April 1, 2026 for weight reduction and long-term maintenance in adults with obesity, or overweight plus a weight-related condition ^{[9] [3]}. It isn’t approved for type 2 diabetes. Unlike semaglutide, orforglipron is a small molecule rather than a peptide, so it doesn’t need the fasting routine: the label says to take it “with or without food.”

In the main trial described in its label, the top dose lowered weight 11.1% at 72 weeks against 2.1% on placebo ^[3]. The trial used an earlier formulation, which the label maps to equivalent Foundayo doses, and it was published as ATTAIN-1 ^[17]. ACHIEVE-3 compared older-formulation orforglipron 12/36 mg with oral semaglutide 7/14 mg in metformin-treated adults with type 2 diabetes. Its open-label results favored orforglipron for A1C, but GI events occurred in 58–59% versus 37–45%, and adverse-event discontinuation in 9–10% versus 4–5%. This Lilly-funded diabetes trial does not establish superiority between every currently marketed weight-treatment dose ^[18]. Foundayo has its own page at orforglipron.

“Oral semaglutide” from compounding pharmacies is a different product

Compounded semaglutide drops, lozenges, dissolving tablets and capsules are not FDA-approved versions of the branded tablets. The OASIS and diabetes-tablet trials tested specified formulations, not every compounded oral preparation. Their results do not establish the absorption, dose equivalence, effectiveness or safety of a pharmacy’s exact product. Ask for evidence about that preparation rather than treating the shared ingredient name as proof.

FDA’s general warning about compounded GLP-1s applies to every form: compounded drugs “are not FDA approved,” and FDA does not review them “for safety, effectiveness or quality before they are marketed” ^[10]. If a program offers “oral semaglutide” for less than the Wegovy pill, ask whether it’s the Novo Nordisk tablet or a compounded product. More on what compounded semaglutide is, and isn’t, is in compounded semaglutide. Questions about low or stretched-out doses are covered in microdosing GLP-1s.